MRD Detection in Hematologic Malignancies

About Personalis

Personalis is transforming cancer management through its advanced genomic sequencing and analysis technologies. The company's core offerings include the NeXT Platform® for comprehensive tumor profiling and the NeXT Personal® assay for highly sensitive MRD detection. Personalis collaborates with leading pharmaceutical companies and research institutions to accelerate drug development and improve patient outcomes. As a publicly traded company, it operates at the intersection of diagnostics, data, and therapeutic development in precision oncology.

Therapeutic Areas